ICS-283: a system for targeted intravenous delivery of siRNA

Authors: Schiffelers, Raymond M¹; Storm, Gert²

Source: Expert Opinion on Drug Delivery, Volume 3, Number 3, May 2006 , pp. 445-454(10)

Buy & download fulltext article:

Price: $99.00 plus tax (Refund Policy)

Abstract:

ICS-283 was developed within Intradigm Corporation as a system that is designed for the systemic delivery of therapeutic small interfering (siRNA) to sites of pathological angiogenesis. The non-viral siRNA delivery system is based on synthetic nanoparticles, known as TargeTran™ (Intradigm Corporation), which functions as a broad-platform technology to deliver siRNA to specific target cells in diseased tissues. The system is constructed to incorporate different functionalities that address critical needs for successful nucleic acid delivery. The TargeTran synthetic vector is a self-assembling, layered nanoparticle that protects and targets siRNA to specific cell types in pathological tissues. At present, ICS-283 is the only antiangiogenic siRNA delivery system that is designed for intravenous administration to treat angiogenesis-driven diseases.

Keywords: angiogenesis; cationic polymers; DNA; small interfering RNA; sterically stabilised nanoparticles; targeted drug delivery

Document Type: Research article

DOI: http://dx.doi.org/10.1517/17425247.3.3.445

Affiliations: 1: 1Assistant professor, Department of Pharmaceutics, Room Z735A, Utrecht Institute for Pharmaceutical Sciences, PO Box 80082, 3508 TB, Utrecht, The Netherlands., Email: r.m.Schiffelers@pharm.uu.nl 2: 2Professor of Advanced Drug Delivery and Drug Targeting, Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, PO Box 80082, 3508 TB, Utrecht, The Netherlands

Publication date: 2006-05-01

More about this publication?